» Articles » PMID: 24851041

Topical Infliximab for the Suppression of Wound Healing Following Experimental Glaucoma Filtration Surgery

Overview
Specialty Pharmacology
Date 2014 May 23
PMID 24851041
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The purpose of this work was to look into the effects of infliximab on wound healing in experimental glaucoma filtration surgery and to compare the antifibrotic effects of this agent to that of mitomycin-C (MMC).

Methods: Twenty-eight male New Zealand White rabbits were randomly assigned to four groups, each including seven rabbits: control group, sham group, MMC group, and infliximab group. The rabbits in the control group were not operated on and did not receive any treatment. The rabbits in the sham group underwent trabeculectomy and had one drop of saline instilled four times a day for 14 days. The rabbits in the MMC treatment group underwent trabeculectomy, and a sponge soaked in 0.4 mg/mL MMC was applied intraoperatively to the scleral surgical site for three minutes. The rabbits in the infliximab treatment group underwent trabeculectomy and one drop of 10 mg/mL infliximab was instilled four times a day for 14 days after surgery. On day 14 of the experiment, the operated and control eyes were enucleated and histologically and immunohistochemically analyzed.

Results: The mean fibroblast and mononuclear cell (MNC) numbers and the mean immunostaining intensities of transforming growth factor-β (TGF-β), fibroblast growth factor-β (FGF-β), and platelet-derived growth factor (PDGF) in the sham group were higher than those of the control group (P<0.01). The mean fibroblast and MNC numbers and the mean immunostaining intensities of TGF-β, FGF-β, and PDGF in the MMC and infliximab groups were statistically significantly lower than those of the sham group (P<0.01). The mean fibroblast and MNC numbers and the mean TGF-β, FGF-β, and PDGF immunostaining intensities of the MMC and infliximab groups were similar (P>0.05).

Conclusion: Our study suggests that topical infliximab effectively suppresses the subconjunctival wound healing response after experimental glaucoma filtration surgery, reducing the MNC and fibroblast numbers and immunostaining intensities of TGF-β, FGF-β, and PDGF.

Citing Articles

Pharmacological Approaches to Modulate the Scarring Process after Glaucoma Surgery.

Collotta D, Colletta S, Carlucci V, Fruttero C, Fea A, Collino M Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375845 PMC: 10305204. DOI: 10.3390/ph16060898.


Aqueous Humor Growth Factor Levels and Trabeculectomy Outcomes in Primary Open-Angle Glaucoma Patients: A 2-Year Prospective Study.

Qian T, Fu M, Ye L, Du J, Xu X, Zhang Z Transl Vis Sci Technol. 2022; 11(10):2.

PMID: 36180030 PMC: 9547364. DOI: 10.1167/tvst.11.10.2.


Targeting Differential Roles of Tumor Necrosis Factor Receptors as a Therapeutic Strategy for Glaucoma.

Lambuk L, Ahmad S, Sadikan M, Nordin N, Kadir R, Abdul Nasir N Front Immunol. 2022; 13:857812.

PMID: 35651608 PMC: 9149562. DOI: 10.3389/fimmu.2022.857812.


Overview of cicatricial modulators in glaucoma fistulizing surgery.

de Oliveira C, Ferreira J Int Ophthalmol. 2020; 40(10):2789-2796.

PMID: 32504309 DOI: 10.1007/s10792-020-01454-w.


Wound Healing Modulation in Glaucoma Filtration Surgery- Conventional Practices and New Perspectives: Antivascular Endothelial Growth Factor and Novel Agents (Part II).

Fan Gaskin J, Nguyen D, Ang G, OConnor J, Crowston J J Curr Glaucoma Pract. 2016; 8(2):46-53.

PMID: 26997808 PMC: 4741169. DOI: 10.5005/jp-journals-10008-1160.


References
1.
Seibold L, Sherwood M, Kahook M . Wound modulation after filtration surgery. Surv Ophthalmol. 2012; 57(6):530-50. DOI: 10.1016/j.survophthal.2012.01.008. View

2.
Imanishi J, Kamiyama K, Iguchi I, Kita M, Sotozono C, Kinoshita S . Growth factors: importance in wound healing and maintenance of transparency of the cornea. Prog Retin Eye Res. 1999; 19(1):113-29. DOI: 10.1016/s1350-9462(99)00007-5. View

3.
YODAIKEN R, Bennett D . OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Occupational Safety and Health Administration. Am J Hosp Pharm. 1986; 43(5):1193-204. View

4.
Verrecchia F, Mauviel A . TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Cell Signal. 2004; 16(8):873-80. DOI: 10.1016/j.cellsig.2004.02.007. View

5.
Lee D, Lee T, CORTES A, Kitada S . Effects of mithramycin, mitomycin, daunorubicin, and bleomycin on human subconjunctival fibroblast attachment and proliferation. Invest Ophthalmol Vis Sci. 1990; 31(10):2136-44. View